Baxter to end Alzheimer's trial of Gammagard

05/8/2013 | Yahoo

Baxter International said it is stopping Phase III trials of Gammagard as an Alzheimer's disease drug after it failed to ameliorate mental decline and functional ability in patients. Gammagard, also known as intravenous immunoglobulin, was the only Alzheimer's treatment in Phase III development. The firm said it will re-evaluate its Alzheimer's program and make a decision after analyzing the trial's full results.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC